Few patients receiving SARS-CoV-2 vaccines may experience rare but serious adverse events such as transverse myelitis (TM). Today, data about TM are scarce. The objective was to investigate reports of TM adverse events related to SARS-CoV-2 vaccines labelled by FDA and EMA, including ChAdOx1nCov-19 (Oxford-AstraZeneca), BNT162b2 (Pfizer/BioNTech), mRNA-1273 (Moderna) and Ad26.COV2.S (Janssen/Johnson \& Johnson) and using the World Health Organization's (WHO) pharmacovigilance database: VigiBase.
Here, investigators use the World Health Organization's (WHO) database of individual safety case reports, to identify cases of TM related to SARS-CoV-2 vaccines.
Study Type
OBSERVATIONAL
Enrollment
580
All patients treated at least with 1 SARS-CoV-2 vaccine
Alexandre Joachim
Caen, Basse Normandie, France
TM reportes related to SARS-CoV-2 vaccine
Time frame: date of the first AE related to a SARS-CoV-2 vaccine to December 10, 2021
Description of the latency period since SARS-CoV-2 vaccine exposure.
Time frame: date of the first AE related to a SARS-CoV-2 vaccine to December 10, 2021
Description of the outcomes following TM
Time frame: date of the first AE related to a SARS-CoV-2 vaccine to December 10, 2021
Description of patients who experienced co-reported adverse events
Time frame: date of the first AE related to a SARS-CoV-2 vaccine to December 10, 2021
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.